Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
– Voyager’s TRACERTM capsid platform validated by Pfizer option exercise –
– Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER –
Related news for (VYGR)
- MoBot’s Stock Market Highlights – 06/02/25 09:00 AM
- Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
- Voyager Therapeutics Announces Pricing of Public Offering
- Voyager Therapeutics Announces Proposed Public Offering
- Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference